Topman Philips: consultation with or about remediation Related articles

Philips is in consultation with the works council of the R&D department, the review of the reorganization by the Enterprise Chamber has therefore been suspended. This says the CEO of Philips Roy Jakobs. According to Jakobs, the reorganization is a major and painful step for the affected employees, but it won’t be able to stop the business model change.

Philips is in consultation with the works council of the R&D department, the review of the reorganization by the Enterprise Chamber has therefore been suspended. This says the CEO of Philips Roy Jakobs. According to Jakobs, the reorganization is a major and painful step for the affected employees, but it won’t be able to stop the business model change. (ANP / ANP / Eva Plevier)

‘We are an innovative company,’ says Jakobs, and that is precisely why this reorganization is needed: to push innovative power ‘forward’, ‘closer to customers and within the company’. Jakobs calls this “an important step we need to take for the future of Philips” and one that is painful for the employees concerned. “Especially in corporate research, which is a bit further away from the market and customers.”

This department has, according to Jakobs, “a great job” “in the past in another business model that we had.” At the same time, according to Jakobs, “it won’t be able to curb the pattern change,” “because that’s how customers expect us to develop for their innovations.”

“Reorganisation is painful for affected employees”

Roy Jakobs, CEO Philips

Business driven innovation

Jakobs points out successful innovations in diagnostic imaging or image-guided therapy that have mainly been developed from the commercial side. ‘Lately we’ve seen great new products come out of the business. Of course with the help of technology that has also been developed in the Corporate Resource Center, but not only’. According to Jakobs, innovation is increasingly a combination of hardware, software and services. He points out that Natlab has always been very focused on hardware development.

Philips was the big winner on the AEX Damrak index on Monday with its price up nearly 11 percent. The health technology group reported increased revenue in the recent quarter but suffered a loss in the millions. That’s because the company set aside €575 million for a possible US claim in connection with the recall of sleep apnea devices. Defective devices, where the insulating foam could crumble, have kept Philips in its grip for years and the company has already released around one billion euros for the recall itself.

Author: Mark VanHarreveld
Source: BNR

LEAVE A REPLY

Please enter your comment!
Please enter your name here

spot_imgspot_img

Hot Topics

Related Articles